A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis.
Roy M FleischmannHenning BliddalFrancisco Javier BlancoThomas J SchnitzerCharles PeterfySu ChenLi WangSheng FengPhilip G ConaghanFrancis BerenbaumJean-Pierre PelletierJohanne Martel-PelletierOle VaeterleinGurjit S KaeleyWei LiuMatthew P KosloskiGwen LevyLanju ZhangJeroen K MedemaMarc C LevesquePublished in: Arthritis & rheumatology (Hoboken, N.J.) (2019)
The limited improvement in the WOMAC pain score and the lack of synovitis improvement with lutikizumab, together with published results from trials of other IL-1 inhibitors, suggest that IL-1 inhibition is not an effective analgesic/antiinflammatory therapy in most patients with knee OA and associated synovitis.